Logo

BG Medicine

True Health Declines to Assume BG Medicine Galectin-3 Supply Agreement

The supply agreement was originally established between BG and the now defunct Health Diagnostics Laboratory, which was formerly BG's biggest customer.

BG Medicine to Delist Stock; Posts 44 Percent Drop in 2015 Revenues

The company, which counts fewer than 300 holders of its common stock, said that it was delisting due to the resources required to remain a public company.

BG Medicine's Shares Plummet After Firm Withdraws Filing for Expanded Use of Galectin-3 Test

BG aimed to use the test to assess risk of fatal cardiovascular events in older adults with no history of cardiovascular, cerebrovascular, or vascular disease.

BG Medicine Amends Galectin-3 Test Sales Agreement With Abbott

The amendment changes product fees Abbott pays to BG Medicine for galectin-3 test sales in exchange for making two payments totaling $1 million.

Nasdaq to Delist BG Medicine’s Stock

The company was unable to comply with requirements including having a minimum bid price of at least $1 per share and stockholder equity of at least $2.5 million.

Nov 17, 2015

BG Medicine Q3 Revenues Down 52 Percent

Sep 15, 2015

Nasdaq to Suspend Trading of BG Medicine's Stock

Aug 14, 2015

BG Medicine Q2 Revenues Fall 37 Percent

Aug 13, 2015

BG Medicine Offering $2.1M in Stocks, Warrants

Jul 9, 2015

BG Medicine Effects One-for-Four Reverse Stock Split

May 14, 2015

BG Medicine Q1 Revenues Shrink 41 Percent, Loss Narrows

May 13, 2015

BG Medicine Inks Financing Agreements for $2.5M

Mar 31, 2015

BG Medicine Q4 Revenues Halved; Firm Files for Additional Galectin-3 Test Indication

Mar 16, 2015

BG Medicine Receives Notice of Non-compliance from Nasdaq

Feb 2, 2015

BG Medicine Granted Continued Listing on Nasdaq as It Works Towards Meeting Requirements

Jan 2, 2015

For Proteomics, 2014 Marked by Interest, Critiques from the Broader Community
Premium

Dec 1, 2014

Nasdaq Issues Second Warning to BG Medicine on Listing Requirement

Nov 13, 2014

BG Medicine Revenues Down 31 Percent in Q3

Oct 20, 2014

BG Medicine Stops Paying Non-Employee Directors

Sep 12, 2014

People in the News: Kelly Gardner, Josh Molho, Brock Siegel, Gary Zweiger, Jenny Rooke, Chris Hadsell, Katleen Verleysen, Anastasia Rader
Premium

Sep 12, 2014

BG Medicine Layoffs Cut Company Headcount in Half; Firm Receives Nasdaq Warning

Aug 14, 2014

BG Medicine Posts 20 Percent Drop in Q2 Revenues

May 16, 2014

BG Medicine Posts 17 Percent Drop in Q1 Revenues as Galectin-3 Sales Continue to Decline
Premium

May 14, 2014

BG Medicine Posts 17 Percent Drop in Q1 Revenues

Apr 3, 2014

BG Medicine Prices Public Offering, Anticipates $8.9M in Net Proceeds

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.